StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) KPIs and segments

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.67−0.01 (-0.01%)

Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Royalty Pharma · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Royalty Pharma: 39 chỉ số vận hành, trong đó có Portfolio Receipts, Portfolio Cash Flow và Full-Year Portfolio Receipts Guidance, lấy từ 188 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Income from financial royalty assets($M)
638595592579550539562533513542523
Other royalty income and revenues($M)
36.135.629.630.528.228.831.831.524.426.473.0
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1
Portfolio Receipts($M)2
890773925874814727839742735608717686
Royalty Receipts($M)15
883768887856811672788729732605705651
Cystic Fibrosis Franchise (Trikafta / Alyftrek / Symdeko / Orkambi / Kalydeco)($M)4
225194253251222194250237207195218207
Trelegy Ellipta($M)4
895898959657857491487160
Tysabri($M)4
676759656856616168646968
Evrysdi($M)4
714780645233535648254520
Xtandi($M)3
514451535042524643394138
Tremfya($M)4
795764564937363934303635
Imbruvica($M)4
313638404144464646495050
Promacta($M)4
9817273833444442304344
Voranigo($M)2
554647393326205
Cabometyx / Cometriq($M)4
242323222120212019171818
Spinraza($M)4
14111214141213151410717
Trodelvy($M)4
161413121210131111101010
Imdelltra($M)4
19171710
Amvuttra($M)4
1098
Other Commercial Products($M)13
1211391081091141099678108889784
Milestones & Other Contractual Receipts($M)
7538183565113331234
Portfolio Cash Flow($M)7
673736722815657641611678617574584637
Credit-Agreement Adjusted EBITDA (Portfolio Liquidity)($M)
840736889816779633738669679560656632
Payments for Operating & Professional Costs($M)1
5037365834941027255486154
Operating & Professional Costs (% of Portfolio Receipts)(%)
5.6%4.8%3.9%6.7%
Net Interest Paid($M)
16701670123-8127-862-1473-5
Distributions to Legacy Non-Controlling Interests — Portfolio Receipts($M)
93867879102898581102928892
Payments for Employee Equity Performance Awards (EPAs)($M)
3510920000000
Distributions from Equity Method Investees($M)
1-1342516336311455
Proceeds from Available-for-Sale Debt Securities($M)
64433313133311
Full-Year Portfolio Receipts Guidance — Upper Bound (Issued in Quarter)($M)5
3,5503,5003,4503,4253,2503,1503,1253,0502,8002,7752,700
Development-Stage Product Candidates in Portfolio
161919201716151415161514
Capital Deployment($M)6
3623495288871,0135951015221,195951931,005
Acquisitions of Financial Royalty Assets($M)
279251452734962114961,195729861,002
Milestone Payments on Acquired Royalties($M)
1305030219502505000
Development-Stage R&D Funding Payments($M)
70982651513015111111
Purchases of Available-for-Sale Debt & Funding Bonds($M)
00010007500015000
Investments in Equity Method Investees($M)
000000000472
Contributions from Legacy Non-Controlling Interests — R&D($M)
000000000000
Announced Royalty Transaction Value — Total($M)2
62501,2501,2001,2502,0002504752941,95594.31,625
Upfront Consideration Announced($M)
275025070596025004751711,63049.31,000
Contingent Milestones & Future Funding Announced($M)
35001,0004952901,750250012332545625
Return on Invested Capital (ROIC, LTM)(%)6
14.3%14.2%14.1%15.8%15.7%
Invested Capital at Work — Average Balance($M)
22,36222,12121,65021,56020,868
Invested Capital at Work — Ending Balance($M)
23,33723,01622,66622,27121,385
Invested Capital at Work — Beginning Balance($M)
21,38621,22520,63320,84820,350
Capital Deployment Added (LTM / Annual)($M)
2,1252,7763,0222,5962,231
Expired Royalties Removed from Invested Capital (LTM / Annual)($M)
1749859901,1731,195
LTM Credit-Agreement Adjusted EBITDA (ROIC Numerator)($M)
3,1873,1333,0453,3963,281
Return on Invested Equity (ROIE, LTM)(%)4
20.2%20.1%19.7%22.8%22.9%
Invested Equity at Work — Average Balance($M)
14,09814,16213,99713,84413,322
Invested Equity at Work — Ending Balance($M)
15,05114,64814,07213,71013,144
Net Debt in Invested Equity Schedule($M)
8,2868,3688,5948,5618,241
LTM Portfolio Cash Flow (ROIE Numerator)($M)
2,8522,8422,7623,154
Total Financial Royalty Assets, Net (Current & Non-Current)($M)4
17,07917,08217,32217,06316,62415,97715,74915,91115,73414,64014,12614,827
Financial Royalty Assets — Gross Carrying Value($M)6
20,02620,11820,04320,46020,09419,43519,41119,70019,35918,50117,77517,892
Financial Royalty Assets — Net Carrying Value (Before Credit Loss Allowance)($M)6
17,37217,34117,52717,27516,84416,19415,97316,14915,93614,80814,26314,965
Cumulative Allowance for Changes in Expected Cash Flows($M)3
-2,654-2,777-2,516-3,186-3,250-3,242-3,438-3,551-3,424-3,693-3,512-2,927
Cumulative Allowance for Credit Losses($M)1
-293-259-205-212-221-217-225-238-202-168-137-138
Quarterly Current-Period Credit Loss Provision, Net($M)
-34.5-87-47.9013.5-33.7-30.90.70
GAAP Cash Collections from Financial Royalty Assets (100% Basis)($M)1
930815916916882727830778792669745747
Other Consolidated Royalty Cash Collections($M)
3832.133.629.129.124.131.829.529.823.226.374.6
Revolution Medicines Co-Funding — Rasonque (Daraxonrasib) Royalty Tranches — Total Commitment($M)3
1,0001,2501,2501,2501,2501,250
Revolution Medicines Co-Funding — Senior Term Loan Tranches — Total Commitment($M)3
750750750750750750
Teva R&D Co-Funding — TEV-'408 (Vitiligo & Celiac Disease) — Total Commitment($M)3
500500500
Johnson & Johnson R&D Co-Funding — JNJ-4804 — Total Commitment($M)3
500500500
Cytokinetics Commercial Launch Funding (Myqorzo / Aficamten) — Total Commitment($M)3
450450450450450450450400
Biogen Phase 3 R&D Funding — Litifilimab (Lupus) — Total Commitment($M)3
250250250250
Cytokinetics Clinical Development Funding (Omecamtiv Mecarbil) — Total Commitment($M)3
100100100100100100100100
Teva Development Co-Funding — Weltruza (TEV-'749) — Total Commitment($M)3
100100100100100100100100
Total Leverage Ratio (Total Debt / Credit-Agreement Adjusted EBITDA)(×)2
2.702.802.903.00
Net Leverage Ratio (Net Debt / Credit-Agreement Adjusted EBITDA)(×)
2.502.602.702.80
Investment-Grade Senior Notes Weighted-Average Duration(năm)
12.012.012.013.0
Class A Ordinary Shares Repurchased(M)2
1.470.871.122.044.218.5022.71.813.483.1200.96
Weighted-Average Price Paid Per Repurchased Share($)
59.2552.1244.7536.853632.5831.9227.7827.4027.0827.32
Remaining Share Repurchase Authorization($M)
1,6001,6871,7331,7831,8582,0102,287465516611695695
Biogen Inc. (BIIB) — Tysabri Global Product Revenue (Upstream SEC XBRL)($M)2
437451442398432455382415406462431465
United States($M)
253271242245248272201230228249214248
International (Ex-U.S.)($M)
184180200153184182181185179214218217
Biogen Inc. (BIIB) — Spinraza Global Product Revenue (Upstream SEC XBRL)($M)2
461402374356374393424421381429341413
United States($M)
246204142169153149154167153157149158
International (Ex-U.S.)($M)
214198232188221243270255228272193255
Gilead Sciences, Inc. (GILD) — Trodelvy Global Product Revenue (Upstream SEC XBRL)($M)3
506457402384357364293355332320309299
United States($M)
336307253251221224181247226224206226
Europe($M)
989295888996757780696848
Rest of World($M)
715754454744373126263624
Alnylam Pharmaceuticals, Inc. (ALNY) — Amvuttra Global Product Revenue (Upstream SEC XBRL)($M)3
1,1301,012890827685492310287259230195175
United States($M)
909809703642530361198183169149130122
Europe($M)
13111911312111292.980.169.865.156.843.730.3
Rest of World (Ex-U.S. & Europe)($M)
9183.774.1644337.731.933.424.824.921.322.8
Exelixis, Inc. (EXEL) — Cabometyx U.S. Net Product Revenue (Upstream SEC XBRL)($M)
603571553545540518511513476433376428
Total Income & Other Revenues (GAAP)($M)7
690674631622609579568594565537568596
Operating Income (GAAP)($M)
411133563388427210534362735270-73.8613
Provision for Changes in Expected Cash Flows & Credit Losses (GAAP)($M)
-34.5-878.70-47.9013.5-36.5-33.7-30.90.70-53.7
R&D Funding Expense (GAAP)($M)
63.297.939.850.550.530150.50.500.500.500.500.50
General & Administrative Expenses (GAAP)($M)
15016216016411918011167.656.754.757.759.2
Net Income Attributable to Royalty Pharma plc (GAAP)($M)
14517.929521528432.22392085441024.80494
Diluted Earnings Per Class A Ordinary Share (GAAP)($)
0.320.040.670.660.070.551.210.230.01
Weighted-Average Diluted Class A Shares(M)
557557557560562578593597598
Net Cash Provided by Operating Activities (GAAP)($M)3
686729718827703364596743704658665773
Net Cash Used in Investing Activities (GAAP)($M)
-286-230-478-848-958-312504-506-1,193-893-86.6-1,000
Net Cash Used in Financing Activities (GAAP)($M)
-699-273-273-300563-508-941-258-3261,157-212-232
Repurchases of Class A Ordinary Shares (GAAP Cash Outflow)($M)
86.344.650.180.514729270952.69780030.2
Total Assets (GAAP)($M)2
19,46119,82019,81519,62119,34718,32317,60818,22318,04217,65716,13116,382
Cash & Cash Equivalents (GAAP)($M)
5148125866199396321,0889299501,765843477
Total Shareholders' Equity (GAAP)($M)
9,7959,7869,9379,7159,6089,4949,77810,34210,2599,7529,86410,084

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Royalty Pharma plc operates on a calendar fiscal year ending December 31 and is the largest buyer of biopharmaceutical royalties worldwide. On May 16, 2025, Royalty Pharma completed the internalization of its external manager, RP Management, LLC, onboarding over 100 employees and structurally reducing cash operating and professional costs as a percentage of Portfolio Receipts.
  • Under US GAAP (ASC 310), most royalties are accounted for as financial royalty assets using the effective-interest method, where non-cash provisions for changes in expected future cash flows create substantial quarterly volatility in GAAP revenue. Management and credit agreements therefore evaluate operational performance through cash Portfolio Receipts, Royalty Receipts, Credit-Agreement Adjusted EBITDA, and Portfolio Cash Flow.
  • Cash royalty receipts generally lag underlying commercial partner end-market drug sales by one calendar quarter (for example, Q2 2026 partner end-market net sales drive Q3 2026 cash royalty collections, while Q3 2026 partner end-market sales provide a direct one-quarter leading indicator for Q4 2026 royalty collections).
  • Single-quarter values for footnote-only cumulative schedules (Note 5 allowance additions/reversals and consolidated GAAP cash collections from financial royalty assets) are derived by subtracting prior cumulative year-to-date Form 10-Q figures from current cumulative Form 10-Q or full-year Form 10-K totals.
  • Standalone parent-company financial statements of Royalty Pharma plc (an English and Welsh holding company) are prepared annually under UK GAAP (FRS 102) rather than US GAAP and reflect holding-company investments without standalone operating revenue; all operational royalties flow through consolidated subsidiaries.

Không hiện vì thiếu các kỳ gần đây (10)

  • Portfolio Receipts, Therapy Royalties & Cash Flow (Key #1) › Portfolio Receipts › Royalty Receipts › Xtandi › Partner-Reported End-Market Net Sales
  • Portfolio Receipts, Therapy Royalties & Cash Flow (Key #1) › Portfolio Receipts › Royalty Receipts › Other Commercial Products › Orladeyo › Partner-Reported End-Market Net Sales
  • Portfolio Receipts, Therapy Royalties & Cash Flow (Key #1) › Portfolio Receipts › Royalty Receipts › Other Commercial Products › Skytrofa › Partner-Reported End-Market Net Sales
  • Portfolio Receipts, Therapy Royalties & Cash Flow (Key #1) › Portfolio Receipts › Royalty Receipts › Other Commercial Products › Yorvipath › Partner-Reported End-Market Net Sales
  • Commercial Products in Portfolio Count ('more than 35 commercial products') — Management consistently discloses the total marketed product count as an open lower-bound inequality rather than an exact integer; all 25 named royalty-generating therapies are instead tracked individually under Royalty Receipts.
  • Annual Initial Diligence Reviews ('>265' in 2020 to '>480' in 2025) — Reported strictly as lower-bound inequalities ('>') on Deal Funnel slides rather than exact counts; exact downstream funnel stages (CDAs signed, in-depth reviews, proposals submitted, and executed transactions) are included.
  • Outbound vs. Inbound Share of In-Depth Reviews (%) — Presentation bar chart prints only one segment label per bar without tabular disclosure of both complementary percentages.
  • Note 5 Individual Carrying Values for Tremfya & Trelegy — Tremfya was grouped into 'Other' in Q1 2026 and Trelegy moved into 'Other' in Q2–Q3 2026 as its amortized carrying balance declined below the individual footnote threshold, breaking 3-quarter continuity.
  • MorphoSys Development Funding Bonds (Sheet 6 Funding Arrangements) — Fully funded and transitioned to fixed quarterly repayment receipts in Q4 2024, so no longer an active unfunded commitment table entry in 2025–2026.
  • Upstream Partner SEC XBRL Product Sales for Vertex (Cystic Fibrosis) & Amgen (Imdelltra) — Latest standardized partner XBRL product breakdown on hand ends in Q2 2026 rather than Q3 2026; partner-reported Q3 2026 end-market sales for both therapies ($3,273M and $406M) are already captured directly under Royalty Pharma's Sheet 4b waterfall.

Dữ liệu cập nhật 2026-11-14.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Royalty Pharma

See a number that looks wrong?